Patents by Inventor Gabriel Martinez

Gabriel Martinez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRROLE INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO
    Publication number: 20230183276
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: February 22, 2023
    Publication date: June 15, 2023
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Gabriel Martinez Botella, Michael Hale, Francois Maltais, Judith Straub, Qing Tang
  • KCNT1 INHIBITORS AND METHODS OF USE
    Publication number: 20230167102
    Abstract: The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.
    Type: Application
    Filed: February 26, 2021
    Publication date: June 1, 2023
    Inventors: Andrew Mark GRIFFIN, Gabriel MARTINEZ BOTELLA, Brian Edward MARRON, Paul S. CHARIFSON
  • OXYSTEROLS AND METHODS OF USE THEREOF
    Publication number: 20230132707
    Abstract: Compounds are provided according to Formula (III): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R5, and n are as defined herein, and at least one hydrogen is replaced with a deuterium. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Application
    Filed: July 8, 2022
    Publication date: May 4, 2023
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro
  • FUSED HETEROARYL COMPOUNDS, AND METHODS THEREOF FOR TREATING DISEASES, DISORDERS, AND CONDITIONS RELATING TO ABERRANT FUNCTION OF A SODIUM CHANNEL
    Publication number: 20230134428
    Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.
    Type: Application
    Filed: January 19, 2022
    Publication date: May 4, 2023
    Inventors: Kiran REDDY, Gabriel MARTINEZ BOTELLA, Andrew Mark GRIFFIN, Brian Edward MARRON
  • Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity
    Patent number: 11629146
    Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: April 18, 2023
    Assignee: PRAXIS PRECISION MEDICINES, INC.
    Inventors: Kiran Reddy, Gabriel Martinez Botella, Andrew Mark Griffin, Brian Edward Marron
  • COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS
    Publication number: 20230113666
    Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof, wherein , A, R1, R2, R3a, R4a, R4b, R5, R7a, and R7b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    Type: Application
    Filed: October 24, 2022
    Publication date: April 13, 2023
    Inventors: Gabriel Martinez Botella, Francesco G. Salituro, Albert Jean Robichaud, Boyd L. Harrison
  • C17, C20, AND C21 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE
    Publication number: 20230116347
    Abstract: Described herein are neuroactive steroids or a pharmaceutically acceptable salt thereof. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a compound described herein and methods of use and treatment, e.g., such as for inducing sedation and/or anesthesia.
    Type: Application
    Filed: June 10, 2022
    Publication date: April 13, 2023
    Inventors: Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Francesco G. Salituro, Andrew Griffin, Maria Jesus Blanco-Pillado
  • Oxysterols and methods of use thereof
    Patent number: 11613556
    Abstract: Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R5, R6, and RG are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: July 27, 2021
    Date of Patent: March 28, 2023
    Assignee: SAGE THERAPEUTICS, INC.
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Andrew Griffin
  • OXYSTEROLS AND METHODS OF USE THEREOF
    Publication number: 20230047157
    Abstract: Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R5, and R8 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Application
    Filed: May 20, 2022
    Publication date: February 16, 2023
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella
  • ION CHANNEL MODULATORS
    Publication number: 20230034917
    Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.
    Type: Application
    Filed: November 25, 2020
    Publication date: February 2, 2023
    Inventors: Kiran REDDY, Gabriel MARTINEZ BOTELLA, Andrew Mark GRIFFIN, Brian Edward MARRON, Carlos LOYA
  • C7, C12, AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE
    Publication number: 20230021308
    Abstract: Described herein are neuroactive steroids of Formula (I), Formula (V), or Formula (IX) or a pharmaceutically acceptable salt thereof; wherein each instance of R2, R3, R4, R5, R6, R7, R11a, R11b, R12, R16, R17, R19, and are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a compound described herein and methods of use and treatment, e.g., such as for inducing sedation and/or anesthesia.
    Type: Application
    Filed: April 28, 2021
    Publication date: January 19, 2023
    Inventors: Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Francesco G. Salituro, Andrew Griffin, Maria Jesus Blanco-Pillado
  • Compositions and methods for treating CNS disorders
    Patent number: 11542297
    Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof, wherein , A, R1, R2, R3a, R4a, R4b, R5, R7a, and R7b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    Type: Grant
    Filed: March 15, 2022
    Date of Patent: January 3, 2023
    Assignee: Sage Therapeutics, Inc.
    Inventors: Gabriel Martinez Botella, Francesco G. Salituro, Albert Jean Robichaud, Boyd L. Harrison
  • Compositions and methods for treating CNS disorders
    Patent number: 11530237
    Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein , A, R1, R2, R3a, R4a, R4b, R5, R7a, and R7b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: December 20, 2022
    Assignee: Sage Therapeutics, Inc.
    Inventors: Gabriel Martinez Botella, Francesco G. Salituro, Albert Jean Robichaud, Boyd L. Harrison
  • Substituted pyridines as ion channel modulators
    Patent number: 11505554
    Abstract: Provided, in part, are compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with the activity of sodium channels. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: November 22, 2022
    Assignee: PRAXIS PRECISION MEDICINES, INC.
    Inventors: Andrew Mark Griffin, Brian Edward Marron, Gabriel Martinez Botella, Kiran Reddy
  • Neuroactive steroids, compositions, and uses thereof
    Patent number: 11498940
    Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein -------, R1, R2, R5, A and L are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: November 15, 2022
    Assignee: Sage Therapeutics, Inc.
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Robert Jason Herr, Robert Borbo Kargbo
  • Compounds and their methods of use
    Patent number: 11492345
    Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: November 8, 2022
    Assignee: PRAXIS PRECISION MEDICINES, INC.
    Inventors: Kiran Reddy, Gabriel Martinez Botella, Andrew Mark Griffin, Brian Edward Marron
  • KCNT1 INHIBITORS AND METHODS OF USE
    Publication number: 20220280476
    Abstract: The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.
    Type: Application
    Filed: May 1, 2020
    Publication date: September 8, 2022
    Applicant: Praxis Precision Medicines, Inc.
    Inventors: Gabriel MARTINEZ BOTELLA, Andrew Mark GRIFFIN, Paul S. CHARIFSON, Kiran REDDY, Michael Kristopher Mathieu KAHLIG, Brian Edward MARRON
  • KCNT1 INHIBITORS AND METHODS OF USE
    Publication number: 20220259193
    Abstract: The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.
    Type: Application
    Filed: May 1, 2020
    Publication date: August 18, 2022
    Applicant: Praxis Precision Medicines, Inc.
    Inventors: Gabriel MARTINEZ BOTELLA, Andrew Mark GRIFFIN, Paul S. CHARIFSON, Kiran REDDY, Michael Kristopher Mathieu KAHLIG, Brian Edward MARRON
  • Oxysterols and methods of use thereof
    Patent number: 11407782
    Abstract: Compounds are provided according to Formula (III): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R5, and n are as defined herein, and at least one hydrogen is replaced with a deuterium. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: August 9, 2022
    Assignee: SAGE THERAPEUTICS, INC.
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro
  • Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto
    Patent number: RE49500
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: April 25, 2023
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Gabriel Martinez Botella, Michael Hale, Francois Maltais, Judith Straub, Qing Tang